SCHEMBL31269047

SCHEMBL31269047

CC(=O)Nc1ccc(-c2nc3c(OC4(C)CC4)ncnc3n2Cc2cc(C)ccn2)c(Cl)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 5/20 0.36
▸ AGPAT2 O15120 1/20 0.35
▸ EGFR P00533 1/20 0.33
▸ ERBB2 P04626 1/20 0.33
▸ LCK P06239 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ RORC P51449 1/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ KDR P35968 1/20 0.32
▸ MCHR1 Q99705 1/20 0.32
▸ HSD11B1 P28845 1/20 0.32
▸ KCNH2 Q12809 1/20 0.32
▸ SCN5A Q14524 1/20 0.32
▸ SCN9A Q15858 1/20 0.32
▸ PIP4K2A P48426 1/20 0.32
▸ TYK2 P29597 1/20 0.31
▸ CNR1 P21554 1/20 0.31
▸ CNR2 P34972 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31269266 0.92 PIK3CD (0.35) PIK3CDAGPAT2NPC1LMNAKDR
SCHEMBL31269321 0.92 PIK3CD (0.34) PIK3CDHSD11B1KCNH2SCN5ASCN9A
SCHEMBL31269339 0.91 PIK3CD (0.34) PIK3CDAGPAT2HSD11B1KCNH2SCN5A
SCHEMBL31269219 0.90 PIK3CD (0.33) PIK3CDALDH1A1NPC1LMNAKDR
SCHEMBL31268904 0.89 PIK3CD (0.41) PIK3CDLMNACNR1CNR2MAPT
SCHEMBL31268946 0.89 PIK3CD (0.34) PIK3CDALDH1A1SMN1; SMN2KCNH2SCN5A
SCHEMBL31269077 0.88 HAVCR2 (0.33) PIK3CDKCNH2SCN5ASCN9ACNR1
SCHEMBL31269475 0.87 PIK3CD (0.37) PIK3CDHSD11B1KCNH2SCN5ASCN9A
SCHEMBL30983779 0.86 KCNH2 (0.36) PIK3CDKCNH2SCN5ASCN9ACNR1
SCHEMBL31269478 0.86 SYK (0.36) PIK3CDKCNH2SCN5ASCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 — — WO disclosed
Send feedback